Overview

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II dose (RP2D) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.